Primary Access & Research

Primary Access & Research We support entrepreneurs by connecting them with investors and helping them to raise money and scale up their businesses.

We also undertake bespoke research focused on industry disruption and political risk.

This politics update looks at New Year policy priorities from both Labour and the Conservatives: Keir Starmer is banking...
16/01/2023

This politics update looks at New Year policy priorities from both Labour and the Conservatives: Keir Starmer is banking on NHS reform being a priority for voters at the next election; if ‘more money’ is increasingly unviable as a solution to public health inefficiencies, can Labour win the argument on the necessary structural changes? As for the Conservatives, we cover how their mission to make Britain a ‘science superpower’ is rolling out. Is innovation the key to Rishi Sunak making the most of the policies he’s inherited, from Levelling Up to Brexit dividends and ‘Global Britain’?



This politics update looks at New Year policy priorities from both Labour and the Conservatives: Keir Starmer is banking on NHS reform being a priority for voters at the next election; if ‘more money’ is increasingly unviable as a solution to public health inefficiencies, can Labour win the argu...

Primary’s 2023 political analysis begins with this contribution from Primary advisor, commentator and historian Simon He...
09/01/2023

Primary’s 2023 political analysis begins with this contribution from Primary advisor, commentator and historian Simon Heffer, outlining Rishi Sunak’s priorities as he starts to raise his profile with voters. Can the UK electorate be soothed by government progress on the economy, NHS and immigration, or will it take more to make the Conservatives electable in 2024-25? And amid priorities of economics, public health and restoring his party’s reputation, is there a chance for Sunak to gain a net ‘legacy’ for himself in areas like labour relations and military spending? All to play for!



Primary’s 2023 political analysis begins with this contribution from Primary advisor, commentator and historian Simon Heffer, outlining Rishi Sunak’s priorities as he starts to raise his profile with voters. Can the UK electorate be soothed by government progress on the economy, NHS and immigrat...

In this, our final scheduled publication of 2022, colleague David Stanistreet reflects on a year in asset markets, polic...
22/12/2022

In this, our final scheduled publication of 2022, colleague David Stanistreet reflects on a year in asset markets, policy choices and eye-catching developments in science, and muses upon what lessons of value may be taken from these to inform portfolio strategy as we head into 2023 and beyond.



In this, our final scheduled publication of 2022, colleague David Stanistreet reflects on a year in asset markets, policy choices and eye-catching developments in science, and muses upon what lessons of value may be taken from these to inform portfolio strategy as we head into 2023 and beyond.

Alzheimer’s disease is a debilitating condition that severely impacts not just the quantity but also the quality of life...
19/12/2022

Alzheimer’s disease is a debilitating condition that severely impacts not just the quantity but also the quality of life of patients and their families. Despite decades of research, most clinical trials of Alzheimer’s drugs, including anti-amyloid antibodies, failed to improve cognitive symptoms. However, recently Eisai and Biogen announced positive results from the phase 3 trial of lecanemab, a monoclonal antibody targeting amyloid-beta. On the face of it, it seems like Biogen and Eisai were finally able to develop the first truly disease-modifying therapy for Alzheimer’s. However, in reality, that may not be the full story. Is lecanemab really effective and what are the concerns around it? What makes it different from all other anti-amyloid drugs that failed in clinical trials?



Alzheimer’s disease is a debilitating condition that severely impacts not just the quantity but also the quality of life of patients and their families. Despite decades of research, most clinical trials of Alzheimer’s drugs, including anti-amyloid antibodies, failed to improve cognitive symptoms...

This politics update provides analysis of UK and American developments: we assess Rishi Sunak’s strategy to regain publi...
15/12/2022

This politics update provides analysis of UK and American developments: we assess Rishi Sunak’s strategy to regain public goodwill for his party by choosing battles on immigration policy and strike response, and also cover the mysterious suspensions of several Labour MPs – is it part of the moderate v socialist infighting? In the US, we preview the election next month of the Speaker of the House: does the small Republican majority hurt the chances of their nominee Kevin McCarthy, and could a shortfall in support open the way for Democrats to choose Nancy Pelosi’s successor?



This politics update provides analysis of UK and American developments: we assess Rishi Sunak’s strategy to regain public goodwill for his party by choosing battles on immigration policy and strike response, and also cover the mysterious suspensions of several Labour MPs – is it part of the mode...

Today most people have heard about gene editing, but have you heard about epigenome editing? Epigenome editing is a nove...
08/12/2022

Today most people have heard about gene editing, but have you heard about epigenome editing? Epigenome editing is a novel way of manipulating gene expression without permanently changing the DNA sequence. The potentially enhanced safety profile and versatility of the epigenome editing platforms have attracted the attention of scientists and investors alike, resulting in the emergence of four new epigenome editing companies, which since 2020 collectively raised $240 million from private and institutional investors. In this report, we highlight eight companies leading the innovation in epigenome editing including Chroma Medicine, Tune Therapeutics, Epic Bio, Sangamo Therapeutics, Omega Therapeutics, Navega Therapeutics and others and discuss how their platforms will lead to the rise of a new type of epigenetic medicines.



Today most people have heard about gene editing, but have you heard about epigenome editing? Epigenome editing is a novel way of manipulating gene expression without permanently changing the DNA sequence.

This update starts a series of research notes covering Labour’s course ahead of the next election, looking at policy, pe...
05/12/2022

This update starts a series of research notes covering Labour’s course ahead of the next election, looking at policy, personnel and messaging choices. Rishi Sunak’s own ‘vision’ will soon be unveiled and the debate will intensify. How Labour responds will influence the polls and if they maintain their advantage.


This update starts a series of research notes covering Labour’s course ahead of the next election, looking at policy, personnel and messaging choices. Rishi Sunak’s own ‘vision’ will soon be unveiled and the debate will intensify. How Labour responds will influence the polls and if they main...

This update explores Poland’s political environment and how its leaders see the world – particularly their relationship ...
29/11/2022

This update explores Poland’s political environment and how its leaders see the world – particularly their relationship with Europe: what is Warsaw’s attitude towards Brussels and will current Polish enthusiasm for the EU persist? Is the country on track to become the continent’s biggest military power? And are there demographic constraints to Poland’s confident 2020s posture?



This update explores Poland’s political environment and how its leaders see the world – particularly their relationship with Europe: what is Warsaw’s attitude towards Brussels and will current Polish enthusiasm for the EU persist?

As the future of cryptocurrency and web3 continues to be debated in light of the current FTX implosion, we highlight the...
24/11/2022

As the future of cryptocurrency and web3 continues to be debated in light of the current FTX implosion, we highlight the web3 report that we published back in March which now seems to be more relevant than ever!



2021 saw a sudden surge in the popularity of cryptocurrencies, NFTs, DeFi, DAOs, smart contracts, and other blockchain applications, largely due to the increased interest from venture capitalists, crypto fans, and A-list celebrities. However, is web3 really as good as it sounds? Or is it simply anot...

This update looks at the Chancellor’s statement and its focus on stability, growth and public services – looking to set ...
21/11/2022

This update looks at the Chancellor’s statement and its focus on stability, growth and public services – looking to set the foundation for recovery in the economy and (for the Conservatives) in the polls. We include a comment from Sir Graham Brady, observe the electoral strategy of delaying spending cuts until after the next election and we note with interest Hunt’s plan for growth based on making Britain a ‘science superpower’.



This update looks at the Chancellor’s statement and its focus on stability, growth and public services – looking to set the foundation for recovery in the economy and (for the Conservatives) in the polls.

Our 45th politics update coincidentally reports on the official 2024 comeback attempt by the 45th President: we examine ...
17/11/2022

Our 45th politics update coincidentally reports on the official 2024 comeback attempt by the 45th President: we examine whether calls by senior Republicans for the party to move on from Donald Trump after the midterms misjudge the feelings of their membership. Would somebody like Ron DeSantis be more ‘unifying’ or do Trump’s base prefer party unity on their terms: one that displaces the McCarthy-McConnell ‘authority’ and completes the GOP’s populist shift at all levels? We finish with an outline of two problems facing the Republicans whoever their next presidential candidate is: a post-Roe polling deficit among young and female voters and a lag behind Democrats in adapting to the expansion of early voting.



Our 45th politics update coincidentally reports on the official 2024 comeback attempt by the 45th President: we examine whether calls by senior Republicans for the party to move on from Donald Trump after the midterms misjudge the feelings of their membership.

This note is a summary of remarks given at a Primary event by the economist Prof. Patrick Minford; he gave his view on w...
16/11/2022

This note is a summary of remarks given at a Primary event by the economist Prof. Patrick Minford; he gave his view on what the abandonment of the Truss/Kwarteng tax plans meant for the outlook of UK growth and argued they could have succeeded with better planning – but also with a Treasury more willing to cooperate. Downbeat on the fiscal agenda of Rishi Sunak and Jeremy Hunt, his discussion continued with examination of what ‘mandates’ meant when prime ministers could change without voting and the dynamic between elected officials and civil servants was so altered as of late.



This note is a summary of remarks given at a Primary event by the economist Prof. Patrick Minford; he gave his view on what the abandonment of the Truss/Kwarteng tax plans meant for the outlook of UK growth and argued they could have succeeded with better planning – but also with a Treasury more w...

Address

London
SW1X8AT

Opening Hours

Monday 9am - 5:30pm
Tuesday 9am - 5:30pm
Wednesday 9am - 5:30pm
Thursday 9am - 5:30pm
Friday 9am - 5:30pm

Telephone

+447761990444

Website

Alerts

Be the first to know and let us send you an email when Primary Access & Research posts news and promotions. Your email address will not be used for any other purpose, and you can unsubscribe at any time.

Shortcuts

Share

Category